 SOLANA BEACH, Calif., Jan. 13, 2021 GLOBE NEWSWIRE -- Evoke Pharma, Inc. Nasdaq: EVOK, a specialty pharmaceutical company focused on treatments for gastrointestinal GI disorders and diseases, today announced that it intends to offer and sell shares of its common stock in a firm commitment underwritten public offering. Evoke also expects to grant to the underwriter for the offering a 45-day option to purchase an additional 15 of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the shares to be sold in the offering are to be sold by Evoke. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 